EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study

Mozhgan Hosseini-Ashrafi, Tim H Clayton, Michelle Herring, Nichola Herety, Peter D Arkwright

Clinical and Experimental Dermatology · 21.05.2024 · 49 (6) · 578-583

DOI: 10.1093/ced/llae013 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 08.01.2024. Verfasst von Mozhgan Hosseini-Ashrafi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Severity of Illness Index. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dupilumab is licensed for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged ≥ 6 months.

Objectives

The aim of this study was to examine real-world outcomes and safety of dupilumab in British children with moderate-to-severe AD attending a tertiary referral paediatric centre.

Methods

Skin and quality of life scores, adverse events and discontinuation rates were assessed. Patients aged ≤ 18 years with moderate-to-severe AD were included if they had skin scores recorded at baseline and at least one follow-up visit. Efficacy and safety were assessed using descriptive statistics.

Results

In this retrospective observational survey, 72 children/teenagers, with a median age of 14 years (range 7–18) were included. Oral systemic immunosuppressants had failed to control AD in 88% of children recruited. All patients commenced on dupilumab had pretreatment eczema skin scores consistent with moderate-to-severe disease, with a median Eczema Area and Severity Index (EASI) score of 25 [interquartile range (IQR) 20–31]. EASI scores decreased by a median of 94% (IQR 82–100) and remained consistently low over 10–52 months of the study, with a median EASI score at final follow-up of 2 (IQR 0–6). Of the 72 children, 8 (11%) were able to discontinue dupilumab as they were in remission. Nineteen (26%) experienced adverse events, most commonly conjunctivitis (12 patients; 17%). Eight (11%) discontinued dupilumab (six with ongoing inflammatory skin flares, one with severe allergic conjunctivitis, one with intercurrent Wilson disease).

Conclusions

Dupilumab was highly effective in treating most children with moderate-to-severe AD with good safety outcomes in the real world. However, 10% of children may need alternative therapy because of drug ineffectiveness or side-effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedSeverity of Illness IndexHumansRetrospective StudiesChildAdolescentFemaleMaleUnited KingdomTreatment OutcomeQuality of LifeDermatologic Agents

Substanzen

Antibodies, Monoclonal, HumanizedDermatologic Agentsdupilumab

Autor:innen und Institutionen

  • Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
  • Department of Paediatric Dermatology, Royal Manchester Children's Hospital, Manchester, UK.
  • Department of Paediatric Allergy & Immunology, Royal Manchester Children's Hospital, Manchester, UK.
  • The Lydia Becker Institute of Immunology and Inflammation, The University of Manchester, Manchester, UK.

Zitieren

APA

Hosseini-Ashrafi, M., Clayton, T. H., Herring, M., Herety, N., & Arkwright, P. D. (2024). Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study. Clinical and Experimental Dermatology, 49(6), 578-583. https://doi.org/10.1093/ced/llae013

Vancouver

Hosseini-Ashrafi M, Clayton TH, Herring M, Herety N, Arkwright PD. Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study. Clinical and Experimental Dermatology. 2024;49(6):578-583. doi:10.1093/ced/llae013

BibTeX
@article{HosseiniAshrafi2024,
  author = {Hosseini-Ashrafi, Mozhgan and Clayton, Tim H and Herring, Michelle and Herety, Nichola and Arkwright, Peter D},
  title = {Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study},
  journal = {Clinical and Experimental Dermatology},
  year = {2024},
  volume = {49},
  number = {6},
  pages = {578--583},
  doi = {10.1093/ced/llae013}
}
Kostenlos starten →